Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Etoposide Phosphate

FDA-approved product (injectable, injection), marketed as Etopophos Preservative Free.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Etoposide Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Lung cancer
  • Lung neoplasm
  • Neoplasm
  • Small cell carcinoma
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Podophyllotoxin derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Etoposide Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Etoposide Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

    NCT07381829 · start 2025-10-27

    Registered record
    Registry ID
    NCT07381829
    Conditions
    Advanced Solid Tumor Cancer
    Interventions
    HC010; Paclitaxel (Chemotherapy); Pemetrexed; Etoposide; Carboplatin/Cisplatin; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-10-27
    Completion
    2026-12-30
    Enrolment
    328

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor Cancer
    InterventionHC010; Paclitaxel (Chemotherapy); Pemetrexed; Etoposide +2 more
    PhasePhase 1
    Registry statusRecruiting

  • A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

    NCT07373964 · start 2025-10-15

    Registered record
    Registry ID
    NCT07373964
    Conditions
    Small Cell Lung Cancer
    Interventions
    Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-15
    Completion
    2027-10-14
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Cancer
    InterventionChidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide
    PhasePhase 2
    Registry statusRecruiting

  • Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

    NCT06830694 · start 2025-05-13

    Registered record
    Registry ID
    NCT06830694
    Conditions
    Small Cell Carcinoma of Lung
    Interventions
    Atezolizumab, Etoposide, Carboplatin, Tarlatamab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-13
    Completion
    2027-06-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Carcinoma of Lung
    InterventionAtezolizumab, Etoposide, Carboplatin, Tarlatamab
    PhasePhase 2
    Registry statusRecruiting

  • Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)

    NCT06943235 · start 2025-04-25

    Registered record
    Registry ID
    NCT06943235
    Conditions
    Limited Stage Small Cell Lung Cancer
    Interventions
    Probiotics; concurrent Hyperfractionated Radiotherapy; Immunotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-04-25
    Completion
    2027-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLimited Stage Small Cell Lung Cancer
    InterventionProbiotics; concurrent Hyperfractionated Radiotherapy; Immunotherapy
    PhasePhase 2
    Registry statusRecruiting

  • International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma

    NCT06839703 · start 2025-03-01

    Registered record
    Registry ID
    NCT06839703
    Conditions
    High-risk GD2-Positive Ewing Sarcoma
    Interventions
    Dinutuximab beta
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2025-03-01
    Completion
    2027-03-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-risk GD2-Positive Ewing Sarcoma
    InterventionDinutuximab beta
    PhasePhase 1
    Registry statusNot yet recruiting

  • Tazemetostat Plus CHOP in 1L T-cell Lymphoma

    NCT06692452 · start 2024-12-24

    Registered record
    Registry ID
    NCT06692452
    Conditions
    Lymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
    Interventions
    Tazemetostat; Doxorubicin; Vincristine; Prednisone; Cytoxan; Carmustine; Etoposide; Cytarabine; Melphalan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-12-24
    Completion
    2032-10-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma +1 more
    InterventionTazemetostat; Doxorubicin; Vincristine; Prednisone +5 more
    PhasePhase 2
    Registry statusWithdrawn

  • Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

    NCT06333314 · start 2024-07-23

    Registered record
    Registry ID
    NCT06333314
    Conditions
    Pancreatic Adenocarcinoma; Ampulla of Vater Carcinoma; Adrenocortical Carcinoma; Neuroendocrine Carcinoma; Soft Tissue Sarcoma; Small Bowel Adenocarcinoma; Duodenum Adenocarcinoma; Gastric Adenocarcinoma
    Interventions
    Dostarlimab; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-07-23
    Completion
    2030-09
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Adenocarcinoma; Ampulla of Vater Carcinoma; Adrenocortical Carcinoma; Neuroendocrine Carcinoma +4 more
    InterventionDostarlimab; Chemotherapy
    PhasePhase 2
    Registry statusRecruiting

  • A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil

    NCT06008353 · start 2024-01-18

    Registered record
    Registry ID
    NCT06008353
    Conditions
    Extensive-stage Small-cell Lung Cancer
    Interventions
    Observational study
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-01-18
    Completion
    2026-08-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-stage Small-cell Lung Cancer
    InterventionObservational study
    PhaseNot recorded
    Registry statusActive not recruiting

  • Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH

    NCT05546060 · start 2022-07-01

    Registered record
    Registry ID
    NCT05546060
    Conditions
    Hemophagocytic Lymphohistiocytosis
    Interventions
    Venetoclax; Dexamethasone; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-07-01
    Completion
    2025-10-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemophagocytic Lymphohistiocytosis
    InterventionVenetoclax; Dexamethasone; Etoposide
    PhasePhase 1
    Registry statusUnknown

  • Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

    NCT05312671 · start 2022-06-27

    Registered record
    Registry ID
    NCT05312671
    Conditions
    Small Cell Neuroendocrine Carcinoma of Bladder; Bladder Cancer; Urothelial Carcinoma Bladder
    Interventions
    Atezolizumab; Carboplatin; Cisplatin; Etoposide; Cystectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-06-27
    Completion
    2029-10
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Neuroendocrine Carcinoma of Bladder; Bladder Cancer; Urothelial Carcinoma Bladder
    InterventionAtezolizumab; Carboplatin; Cisplatin; Etoposide +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

    NCT06418087 · start 2022-05-27

    Registered record
    Registry ID
    NCT06418087
    Conditions
    Pulmonary Large-cell Neuroendocrine Carcinoma
    Interventions
    Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-05-27
    Completion
    2026-12-31
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Large-cell Neuroendocrine Carcinoma
    InterventionDurvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]
    PhasePhase 2
    Registry statusRecruiting

  • Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

    NCT05142865 · start 2022-01-14

    Registered record
    Registry ID
    NCT05142865
    Conditions
    Advanced or Metastatic EP-NEC
    Interventions
    Camrelizumab; Etoposide; Carboplatin; Cisplatin; Apatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-01-14
    Completion
    2024-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced or Metastatic EP-NEC
    InterventionCamrelizumab; Etoposide; Carboplatin; Cisplatin +1 more
    PhasePhase 2
    Registry statusUnknown

  • A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    NCT04501614 · start 2021-02-24

    Registered record
    Registry ID
    NCT04501614
    Conditions
    Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL); Ph+ Mixed Phenotype Acute Leukemia (MPAL); Philadelphia Chromosome-Like ALL (Ph-like ALL)
    Interventions
    Ponatinib; Chemotherapy Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2021-02-24
    Completion
    2024-07-19
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL); Ph+ Mixed Phenotype Acute Leukemia (MPAL); Philadelphia Chromosome-Like ALL (Ph-like ALL)
    InterventionPonatinib; Chemotherapy Agents
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

    NCT04728230 · start 2021-01-05

    Registered record
    Registry ID
    NCT04728230
    Conditions
    Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Carboplatin; Durvalumab; Etoposide; Olaparib; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2021-01-05
    Completion
    2027-12-31
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    InterventionCarboplatin; Durvalumab; Etoposide; Olaparib +1 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL

    NCT04066920 · start 2019-10-01

    Registered record
    Registry ID
    NCT04066920
    Conditions
    Primary Central Nervous System Lymphoma
    Interventions
    IBER salvage chemotherapy followed by ibrutinib maintenance therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-10-01
    Completion
    2023-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Central Nervous System Lymphoma
    InterventionIBER salvage chemotherapy followed by ibrutinib maintenance therapy
    PhasePhase 2
    Registry statusUnknown